A study on multi-dose pharmacokinetics of gatifloxacin mesylate in healthy volunteers

王睿,朱曼,方翼,王中孝,裴斐,柴栋,聂卫民
DOI: https://doi.org/10.3969/j.issn.1001-8689.2003.07.012
2003-01-01
Abstract:Objective To investigate the pharmacokinetics of gatifloxacin mesylate after multi-dose i. v in Chinese healthy volunteers. Methods The protocoal was designed according to GCP after passing the ethical committee and all volunteers signed the informed consent. The healthy male volunteers in 18-40 years old were given i. v 400mg gatifloxacin mesylate once a day for 14 days. The blood were collected before and at 0.67, 1.33, 2, 2.33, 2.5, 3, 4, 6, 8, 10, 14, 24h after i. v on the 1st and 8th day. The peak and trough concentrations were monitored everyday. The plasma concentrations were determined by HPLC method and the parameters of pharmacokinetics were calculated by 3P97 software. Results It is a two-compartment model in vivo after gatifloxacin was administrated in volunteers. The AUC 0-∞ and AUC 0-t on the 8th day were significantly increased compared with the 1st day, but there was no significant difference between AUC 0-r, of 8th day vs. AUC 0-∞ of 1st day and the other parameters C max, T 1/2β, Vd either. The mean stable concentration C av was (0.971± 0.184) mg/L. The accumulation ratio was (1.281±0.328) and fluctuation coefficient was (1.702±0.056). There was no significant difference in peak and trough concentrations of 14th day and the 1st day. No serious adverse effect was observed in volunteers. Conclusion Effective concentration in vivo could achieved after intravenous infusion of 400mg gatifloxacin methanesulfonate once a day for 14 days and no accumulation in human body was observed after 14 day administration. The dosing schedule could be recommended.
What problem does this paper attempt to address?